

## Appendix: Tables

1.	Sales January to March 2020 and 2019 .....	2
2.	Quarterly sales and constant exchange rate sales growth by Division in 2020 and 2019.....	3
3.	Pharmaceuticals Division – Top-selling pharmaceuticals sales and constant exchange rate growth Q1 2020 vs. Q1 2019 .....	4
4.	Pharmaceuticals Division – New products sales and constant exchange rate growth Q1 2020 vs. Q1 2019 .....	5
5.	Top 20 Pharmaceuticals Division product sales and constant exchange rate growth Q1 2020 vs. Q1 2019 .....	6
6.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth .....	7
7.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States.....	8
8.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe.....	9
9.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan .....	10
10.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International* .....	11

**1. Sales January to March 2020 and 2019**

CHF millions	Three months ended 31 March		% change	
	2020	2019	At CER	In CHF
Pharmaceuticals Division	12,262	11,927	7	3
United States	6,616	6,623	3	0
Europe	2,264	2,101	14	8
Japan	948	941	3	1
International*	2,434	2,262	16	8
Diagnostics Division	2,881	2,899	5	-1
Roche Group	15,143	14,826	7	2

\* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, others

2. Quarterly sales and constant exchange rate sales growth by Division in 2020 and 2019

CHF millions	Q1 2019	% change vs. Q1 2018	Q2 2019	% change vs. Q2 2018	Q3 2019	% change vs. Q3 2018	Q4 2019	% change vs. Q4 2018	Q1 2020	% change vs. Q1 2019
Pharmaceuticals Division	11,927	10	12,267	11	12,365	15	11,957	8	12,262	7
United States	6,623	14	6,747	13	6,666	14	6,675	11	6,616	3
Europe	2,101	-6	2,120	-2	2,089	5	2,143	6	2,264	14
Japan	941	7	1,047	12	1,088	14	1,067	3	948	3
International*	2,262	17	2,353	16	2,522	27	2,072	2	2,434	16
Diagnostics Division	2,899	1	3,376	4	3,232	6	3,443	1	2,881	5
Roche Group	14,826	8	15,643	9	15,597	13	15,400	6	15,143	7

\*Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, others

### 3. Pharmaceuticals Division – Top-selling pharmaceuticals sales and constant exchange rate growth Q1 2020 vs. Q1 2019

Top-selling pharmaceuticals January - March 2020	Total		United States		Europe		Japan		International*	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Avastin	1,497	-13	586	-27	423	-3	181	-5	307	5
MabThera/Rituxan	1,389	-15	973	-14	123	-24	17	-39	276	-9
Herceptin	1,207	-24	475	-38	193	-32	40	-26	499	4
Ocrevus	1,112	38	898	29	156	79	-	-	58	119
Perjeta	1,011	22	395	-1	307	21	74	49	235	83
Actemra/RoActemra	666	30	296	44	209	27	89	6	72	27
Tecentriq	644	99	376	79	145	169	69	111	54	101
Hemlibra	521	146	353	119	78	216	74	207	16	**
Xolair	468	3	468	3	-	-	-	-	-	-
Kadcyla	428	55	204	68	132	43	18	3	74	63

\* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, others

\*\* Over 500%

4. Pharmaceuticals Division – New products sales and constant exchange rate growth Q1 2020 vs. Q1 2019

New products January - March 2020	Total		United States		Europe		Japan		International*	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Erivedge	73	25	48	27	18	14	-	-	7	45
Perjeta	1,011	22	395	-1	307	21	74	49	235	83
Kadcyla	428	55	204	68	132	43	18	3	74	63
Gazyva/Gazyvaro	165	49	79	48	56	57	15	95	15	7
Esbriet	292	22	202	20	74	28	-	-	16	23
Cotellic	15	5	3	-16	7	-19	-	-	5	111
Alecensa	268	43	84	29	66	51	53	15	65	97
Tecentriq	644	99	376	79	145	169	69	111	54	101
Ocrevus	1,112	38	898	29	156	79	-	-	58	119
Hemlibra	521	146	353	119	78	216	74	207	16	**
Xofluza	28	371	26	353	-	-	-	-	2	**
Polivy	38	**	27	-	10	**	-	-	1	-
Rozlytrek	3	-	3	-	-	-	-	-	-	-

\* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, others

\*\* Over 500%

5. Top 20 Pharmaceuticals Division product sales and constant exchange rate growth Q1 2020 vs. Q1 2019

CHF millions	Total		United States		Europe		Japan		International*	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Avastin	1,497	-13	586	-27	423	-3	181	-5	307	5
MabThera/Rituxan	1,389	-15	973	-14	123	-24	17	-39	276	-9
Herceptin	1,207	-24	475	-38	193	-32	40	-26	499	4
Ocrevus	1,112	38	898	29	156	79	-	-	58	119
Perjeta	1,011	22	395	-1	307	21	74	49	235	83
Actemra/RoActemra	666	30	296	44	209	27	89	6	72	27
Tecentriq	644	99	376	79	145	169	69	111	54	101
Hemlibra	521	146	353	119	78	216	74	207	16	**
Xolair	468	3	468	3	-	-	-	-	-	-
Kadcyla	428	55	204	68	132	43	18	3	74	63
Activase/TNKase	390	11	376	10	-	-	-	-	14	27
Lucentis	387	-13	387	-13	-	-	-	-	-	-
Esbriet	292	22	202	20	74	28	-	-	16	23
Alecensa	268	43	84	29	66	51	53	15	65	97
Pulmozyme	191	10	128	10	37	12	-	-	26	8
CellCept	166	7	18	-15	48	15	19	0	81	11
Gazyva	165	49	79	48	56	57	15	95	15	7
Tamiflu	149	-13	6	-75	24	-8	29	-59	90	70
Mircera	126	-8	-	-	17	6	37	-17	72	-6
Madopar	98	5	-	-	29	13	-	-	69	2

\* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, others

\*\* Over 500%

6. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth

CHF millions	Q1 2019	% change vs. Q1 2018	Q2 2019	% change vs. Q2 2018	Q3 2019	% change vs. Q3 2018	Q4 2019	% change vs. Q4 2018	Q1 2020	% change vs. Q1 2019
Avastin	1,798	9	1,861	6	1,806	8	1,608	-6	1,497	-13
MabThera/Rituxan	1,694	-3	1,645	-5	1,620	-1	1,518	-6	1,389	-15
Herceptin	1,666	-6	1,598	-12	1,535	-7	1,240	-24	1,207	-24
Ocrevus	836	67	899	59	929	48	1,044	55	1,112	38
Perjeta	868	41	887	29	910	33	857	16	1,011	22
Actemra/RoActemra	534	6	601	10	571	9	605	5	666	30
Tecentriq	336	135	446	146	515	154	578	136	644	99
Hemlibra	219	*	316	*	386	*	459	313	521	146
Xolair	469	1	503	2	513	3	484	0	468	3
Kadcyla	291	24	345	42	369	54	388	57	428	55
Activase/TNKase	362	7	324	-3	334	5	312	0	390	11
Lucentis	457	11	471	9	442	7	456	7	387	-13
Esbriet	250	10	282	13	281	6	316	9	292	22
Alecensa	196	61	225	41	235	50	220	11	268	43
Pulmozyme	182	6	189	0	191	7	189	-5	191	10
CellCept	163	4	162	-4	177	3	154	-3	166	7
Gazyva	115	35	126	38	149	45	162	51	165	49
Tamiflu	179	-40	48	110	59	369	91	104	149	-13
Mircera	142	16	140	10	167	11	142	5	126	-8
Madopar	102	16	87	-1	94	22	84	9	98	5

\* Over 500%

7. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States

CHF millions	Q1 2019	% change vs. Q1 2018	Q2 2019	% change vs. Q2 2018	Q3 2019	% change vs. Q3 2018	Q4 2019	% change vs. Q4 2018	Q1 2020	% change vs. Q1 2019
Avastin	824	12	806	7	742	1	647	-11	586	-27
MabThera/Rituxan	1,168	9	1,113	-1	1,108	4	1,099	1	973	-14
Herceptin	791	3	718	-8	665	-6	533	-24	475	-38
Ocrevus	715	54	741	46	760	35	833	44	898	29
Perjeta	412	36	376	9	370	8	370	4	395	-1
Actemra/RoActemra	212	5	248	11	236	11	248	6	296	44
Tecentriq	216	91	292	158	329	198	343	146	376	79
Hemlibra	166	*	215	*	254	*	308	302	353	119
Xolair	469	1	503	2	513	3	484	0	468	3
Kadcyla	125	39	153	62	170	87	187	108	204	68
Activase/TNKase	351	7	310	-4	320	5	297	-1	376	10
Lucentis	457	11	471	9	442	7	456	7	387	-13
Esbriet	174	7	200	9	199	0	233	6	202	20
Alecensa	67	14	82	5	82	15	98	23	84	29
Pulmozyme	119	6	134	-1	138	9	136	-4	128	10
CellCept	21	-20	22	-25	23	-30	17	-15	18	-15
Gazyva	55	22	55	8	65	24	74	48	79	48
Tamiflu	24	-86	7	*	-	-	12	*	6	-75
Mircera	-	-	-	-	-	-	-	-	-	-
Madopar	-	-	-	-	-	-	-	-	-	-

\* Over 500%



8. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe

CHF millions	Q1 2019	% change vs. Q1 2018	Q2 2019	% change vs. Q2 2018	Q3 2019	% change vs. Q3 2018	Q4 2019	% change vs. Q4 2018	Q1 2020	% change vs. Q1 2019
Avastin	461	1	459	3	435	4	439	1	423	-3
MabThera/Rituxan	171	-38	152	-35	147	-26	120	-33	123	-24
Herceptin	300	-44	268	-47	233	-42	212	-39	193	-32
Ocrevus	92	232	119	149	127	154	157	112	156	79
Perjeta	267	27	274	28	264	18	287	21	307	21
Actemra/RoActemra	174	4	181	8	172	3	178	3	209	27
Tecentriq	57	158	77	112	93	113	122	172	145	169
Hemlibra	26	450	37	*	45	211	57	202	78	216
Xolair	-	-	-	-	-	-	-	-	-	-
Kadcyla	97	9	107	18	108	20	120	28	132	43
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Lucentis	-	-	-	-	-	-	-	-	-	-
Esbriet	62	14	66	18	66	26	69	16	74	28
Alecensa	46	182	50	154	57	164	59	58	66	51
Pulmozyme	35	8	33	3	31	2	33	-2	37	12
CellCept	44	2	43	-2	43	3	43	-1	48	15
Gazyva	38	31	42	31	44	30	50	38	56	57
Tamiflu	28	38	13	*	34	*	6	145	24	-8
Mircera	17	-11	17	-7	17	-8	16	-8	17	6
Madopar	27	3	29	9	28	6	29	7	29	13

\* Over 500%

9. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan

CHF millions	Q1 2019	% change vs. Q1 2018	Q2 2019	% change vs. Q2 2018	Q3 2019	% change vs. Q3 2018	Q4 2019	% change vs. Q4 2018	Q1 2020	% change vs. Q1 2019
Avastin	194	2	230	4	241	9	206	-13	181	-5
MabThera/Rituxan	28	-50	30	-42	26	-45	25	-37	17	-39
Herceptin	56	-9	67	6	62	-1	58	-15	40	-26
Ocrevus	-	-	-	-	-	-	-	-	-	-
Perjeta	51	74	69	99	81	125	79	67	74	49
Actemra/RoActemra	86	13	102	11	107	13	103	1	89	6
Tecentriq	33	-	42	169	50	66	63	68	69	111
Hemlibra	25	-	57	*	71	*	79	472	74	207
Xolair	-	-	-	-	-	-	-	-	-	-
Kadcyla	18	12	22	11	22	10	20	-5	18	3
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Lucentis	-	-	-	-	-	-	-	-	-	-
Esbriet	-	-	-	-	-	-	-	-	-	-
Alecensa	47	24	58	16	57	14	55	-1	53	15
Pulmozyme	-	-	-	-	-	-	1	14	-	-
CellCept	19	8	23	7	21	1	22	-1	19	0
Gazyva	8	-	13	-	25	390	20	145	15	95
Tamiflu	71	-6	1	153	-	-	25	50	29	-59
Mircera	45	3	55	4	51	-6	51	-14	37	-17
Madopar	-	-	-	-	-	-	-	-	-	-

\* Over 500%

10. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International\*

CHF millions	Q1 2019	% change vs. Q1 2018	Q2 2019	% change vs. Q2 2018	Q3 2019	% change vs. Q3 2018	Q4 2019	% change vs. Q4 2018	Q1 2020	% change vs. Q1 2019
Avastin	319	16	366	10	388	29	316	0	307	5
MabThera/Rituxan	327	-4	350	8	339	3	274	-11	276	-9
Herceptin	519	26	545	17	575	20	437	-16	499	4
Ocrevus	29	261	39	173	42	118	54	155	58	119
Perjeta	138	83	168	73	195	122	121	19	235	83
Actemra/RoActemra	62	10	70	15	56	16	76	15	72	27
Tecentriq	30	262	35	127	43	132	50	109	54	101
Hemlibra	2	-	7	-	16	**	15	**	16	**
Xolair	-	-	-	-	-	-	-	-	-	-
Kadcyla	51	32	63	62	69	78	61	50	74	63
Activase/TNKase	11	-10	14	6	14	2	15	8	14	27
Lucentis	-	-	-	-	-	-	-	-	-	-
Esbriet	14	37	16	49	16	20	14	31	16	23
Alecensa	36	278	35	177	39	154	8	-64	65	97
Pulmozyme	28	4	22	0	22	5	19	-15	26	8
CellCept	79	13	74	-1	90	17	72	-1	81	11
Gazyva	14	31	16	101	15	31	18	43	15	7
Tamiflu	56	55	27	30	25	270	48	86	90	70
Mircera	80	35	68	21	99	27	75	28	72	-6
Madopar	75	28	58	2	66	40	55	11	69	2

\* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, others

\*\* Over 500%